Results 1 to 10 of about 3,024,177 (290)

Angioedema, ACE inhibitor and COVID-19. [PDF]

BMJ Case Rep, 2020
SARS-CoV-2, the virus responsible for COVID-19, binds to the ACE2 receptors. ACE2 is thought to counterbalance ACE in the renin-angiotensin system. While presently it is advised that patients should continue to use ACE inhibitors or angiotensin receptor ...
Grewal E, Sutarjono B, Mohammed I.
europepmc   +2 more sources

SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be ameliorated by ACE inhibitor Captopril. [PDF]

Antiviral Res, 2023
Huang X, Fan W, Sun J, Yang J, Zhang Y, Wang Q, Li P, Zhang Y, Zhang S, Li H, Wang J, Feng L, Zhao J, Chen L, Qu L.   +14 more
europepmc   +3 more sources

ACE inhibitors

Cardiovascular Drugs and Therapy, 1993
There are chemical differences among angiotensin-converting enzyme (ACE) inhibitors that profoundly influence the pharmacokinetics and dynamics of different drugs. Differences in potency, affinity, and duration of action can be readily identified.
  +12 more sources

Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics

European Journal of Heart Failure, 2021
Patients surviving an acute myocardial infarction (AMI) are at risk of developing symptomatic heart failure (HF) or premature death. We hypothesized that sacubitril/valsartan, effective in the treatment of chronic HF, prevents development of HF and ...
K. Jering, B. Claggett, M. Pfeffer, C. Granger, L. Køber, E. Lewis, A. Maggioni, D. Mann, J. McMurray, J. Rouleau, S. Solomon, P. Steg, P. Meer, M. Wernsing, Katherine Carter, Weinong Guo, Yinong Zhou, M. Lefkowitz, J. Gong, Yi Wang, B. Merkely, S. Macin, U. Shah, J. Nicolau, E. Braunwald   +24 more
semanticscholar   +1 more source

Kidney and Lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19

bioRxiv, 2020
Background There have been concerns that ACE inhibitors and Ang II receptor blockers may cause an increase in ACE2, the main receptor for SARs-CoV-2.
J. Wysocki, Enrique Lores, M. Ye, M. Soler, D. Batlle   +4 more
semanticscholar   +1 more source

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies

Internal and Emergency Medicine, 2020
SARS-CoV-2 is characterized by a spike protein allowing viral binding to the angiotensin-converting enzyme (ACE)-2, which acts as a viral receptor and is expressed on the surface of several pulmonary and extra-pulmonary cell types, including cardiac ...
A. Albini, G. Dİ GUARDO, D. Noonan, M. Lombardo   +3 more
semanticscholar   +1 more source

ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic

HYPERTENSION, 2020
Potential but unconfirmed risk factors for coronavirus disease 2019 (COVID-19) in adults and children may include hypertension, cardiovascular disease, and chronic kidney disease, as well as the medications commonly prescribed for these conditions, ACE ...
A. South, T. Brady, J. Flynn
semanticscholar   +1 more source

ACE inhibitors [PDF]

British Journal of Clinical Pharmacology, 2002
Edited by P. D’Orlèans‐Juste & G. E. Plante
 Published by Birkhauser [Milestones in drug therapy series]
 187 pages, price @116, ISBN 3‐7643‐5982 ...
N. F. Kelland, D. J. Webb
openaire   +1 more source

Prodrug ACE Inhibitors [PDF]

Circulation, 1998
To the Editor: In a recent issue of Circulation , Brown and Vaughan1 reviewed ACE inhibitors. They stated that captopril and lisinopril are active drugs and listed 7 other ACE inhibitors approved in the United States that are inactive prodrugs until metabolized in the liver.
openaire   +2 more sources

A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice

Journal of Biological Chemistry, 2019
Inhibition of angiotensin-converting enzyme (ACE) is a strategy used worldwide for managing hypertension. In addition to converting angiotensin I to angiotensin II, ACE also converts neurotoxic β-amyloid protein 42 (Aβ42) to Aβ40.
Shuyu Liu, F. Ando, Yukari Fujita, Junjun Liu, Tomoji Maeda, Xuefeng Shen, Kota Kikuchi, Aoi Matsumoto, Mirai Yokomori, Chiaki Tanabe-Fujimura, H. Shimokata, M. Michikawa, H. Komano, K. Zou   +13 more
semanticscholar   +1 more source